Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Collegium closes USD 20 million series D equity financing

July 16, 2008

FDA approves Roxane's NDA for morphine sulfate tablets and oral solution

July 16, 2008

Sigma-Tau's 5-HT6 receptor ligand shows antidepressant-like activity in vivo

July 16, 2008

Glenmark's neuropathic pain candidate, GRC-10693, to enter phase I trials

July 16, 2008

Rottapharm's new analgesic CR-4056 modulates neurotransmitter release in vitro

July 16, 2008

Results from animal studies indicate potential use for AMN-082 in treating inflammatory pain

July 16, 2008

Novel therapeutic agents for neurologic disorders reported in recent patents

July 16, 2008

Map commences phase III MAP-0004 trial in patients with migraine

July 15, 2008

Clinical results from blonanserin for the treatment of cognitive deficits in schizophrenia

July 15, 2008

A novel positive allosteric modulator of nAChR7 under preclinical development for schizophrenia

July 15, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...